4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.79) per share. This is a 3.66 percent increase over losses of $(0.82) per share from the same period last year.
Why Hims & Hers Health Stock Is Rising Today
After the market close on Monday, Hims & Hers Health reported strong first-quarter results that included revenue of $278.2 million, representing a 46% increase from $190.8 million in the first quarter of 2023. The number beat analyst estimates of $270.382 million.
